Twelve percent of American adults take GLP-1 weight loss drugs
It is not a hormone
HCPF is moving toward greater integration of physical and behavioral health, and some aspects of the BHO model are expected to change, although capitation will likely remain
Of these trials, four compared DPP-4 inhibitors against placebo (SAVOR-TIMI 53, EXAMINE, TECOS, CARMELINA), eight compared GLP-1RA against placebo (ELIXA, LEADER, SUSTAIN-6, EXSCEL, HARMONY, REWIND, PIONEER 6, AMPLITUTE-O) and eleven compared SGLT-2 inhibitors against placebo (EMPA-REG, CANVAS, DECLARE, CREDENCE, DAPA-HF, DAPA CKD, VERTIS-CV, EMPEROR-R, SCORED, SOLOIST-WHF, EMPEROR-P)
Rybelsus is a once-a-day tablet licensed only for type 2 diabetes, where it leads to more modest weight loss of around 4 kg (4-5%)